| scholarly article | Q13442814 |
| P50 | author | Ian J. Woolley | Q43444905 |
| Lewis Kuller | Q88077314 | ||
| Nathan W Cummins | Q88334168 | ||
| P2093 | author name string | Russell P Tracy | |
| Jacqueline Neuhaus | |||
| James D Neaton | |||
| Jason V Baker | |||
| Daniel Duprez | |||
| Clara Lehmann | |||
| David Dalmau | |||
| Ann Sullivan | |||
| Kathleen Brummel-Ziedins | |||
| Jack DeHovitz | |||
| INSIGHT SMART Study Team | |||
| P2860 | cites work | CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract | Q22242965 |
| Microbial translocation is a cause of systemic immune activation in chronic HIV infection | Q22251054 | ||
| Cardiovascular disease. Does inflammation cut to the heart of the matter? | Q28192777 | ||
| Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study | Q28213764 | ||
| Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor composition | Q28222922 | ||
| Inflammatory and coagulation biomarkers and mortality in patients with HIV infection | Q28473903 | ||
| Inflammation, coagulation and cardiovascular disease in HIV-infected individuals | Q28483645 | ||
| CD4+ count-guided interruption of antiretroviral treatment | Q29619489 | ||
| Platelet count kinetics following interruption of antiretroviral treatment | Q33403565 | ||
| Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation | Q33597485 | ||
| Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection | Q33857515 | ||
| Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study | Q34011661 | ||
| HIV Infection, Inflammation, Immunosenescence, and Aging | Q34150710 | ||
| Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort | Q34204026 | ||
| Peptide Bond Cleavages and Loss of Functional Activity during Inactivation of Factor Va and Factor VaR506Q by Activated Protein C | Q34305158 | ||
| Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection | Q34423991 | ||
| Thrombin generation profiles in deep venous thrombosis | Q34469944 | ||
| The plasma hemostatic proteome: thrombin generation in healthy individuals | Q34481022 | ||
| Platelets in atherothrombosis | Q34986345 | ||
| HIV mono-infection is associated with FIB-4 - A noninvasive index of liver fibrosis - in women | Q35019825 | ||
| Thrombin generation in chronic obstructive pulmonary disease: dependence on plasma factor composition | Q35243446 | ||
| HIV infection is associated with decreased thrombin generation | Q35845337 | ||
| Mucosal simian immunodeficiency virus transmission in African green monkeys: susceptibility to infection is proportional to target cell availability at mucosal sites | Q35868061 | ||
| Thrombin generation and bleeding in haemophilia A | Q36090217 | ||
| The prothrombotic phenotypes in familial protein C deficiency are differentiated by computational modeling of thrombin generation | Q36229803 | ||
| Markers of endothelial dysfunction, coagulation and tissue fibrosis independently predict venous thromboembolism in HIV. | Q36377944 | ||
| Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study | Q36445470 | ||
| Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir | Q36578046 | ||
| Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study | Q36922487 | ||
| Peak thrombin generation and subsequent venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE) study | Q37390567 | ||
| Association of C-reactive protein and HIV infection with acute myocardial infarction | Q37390630 | ||
| The coagulopathy of chronic liver disease | Q37900633 | ||
| Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection | Q39244103 | ||
| Characterization of a CD4-independent clinical HIV-1 that can efficiently infect human hepatocytes through chemokine (C-X-C motif) receptor 4. | Q39946293 | ||
| Human Immunodeficiency Virus–Induced Apoptosis of Human Hepatocytes via CXCR4 | Q40615656 | ||
| The effect of Arg306-->Ala and Arg506-->Gln substitutions in the inactivation of recombinant human factor Va by activated protein C and protein S. | Q42201669 | ||
| The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection. | Q42280383 | ||
| Plasma hemostatic factors and endothelial markers in four racial/ethnic groups: the MESA study. | Q43458565 | ||
| Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). | Q43864459 | ||
| Neurosteroid-mediated regulation of brain innate immunity in HIV/AIDS: DHEA-S suppresses neurovirulence | Q45019198 | ||
| Protein S deficiency in men with long-term human immunodeficiency virus infection | Q45773588 | ||
| The role of secondary lymphatic tissue in immune deficiency of HIV infection. | Q51961299 | ||
| CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection. | Q52014394 | ||
| A model for the stoichiometric regulation of blood coagulation. | Q52044713 | ||
| Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. | Q53855050 | ||
| Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe | Q57877234 | ||
| Acquired protein S deficiency: correlation with advanced disease in HIV-1-infected patients | Q68054564 | ||
| Identification and quantitation of HIV-1 in the liver of patients with AIDS | Q68068646 | ||
| Multiple active forms of thrombin. IV. Relative activities of meizothrombins | Q68819101 | ||
| Role of the membrane in the inactivation of factor Va by activated protein C | Q72661630 | ||
| Functional characterization of recombinant human meizothrombin and Meizothrombin(desF1). Thrombomodulin-dependent activation of protein C and thrombin-activatable fibrinolysis inhibitor (TAFI), platelet aggregation, antithrombin-III inhibition | Q73101168 | ||
| A model describing the inactivation of factor Va by APC: bond cleavage, fragment dissociation, and product inhibition | Q77807397 | ||
| Acquired protein C and protein S deficiency in HIV-infected patients | Q79341074 | ||
| Increased levels of platelet microparticles in HIV-infected patients with good response to highly active antiretroviral therapy | Q84307947 | ||
| P433 | issue | 4 | |
| P921 | main subject | HIV | Q15787 |
| P304 | page(s) | e000264 | |
| P577 | publication date | 2013-07-29 | |
| P1433 | published in | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease | Q19880670 |
| P1476 | title | HIV replication alters the composition of extrinsic pathway coagulation factors and increases thrombin generation | |
| P478 | volume | 2 |
| Q39009201 | Acute coronary syndromes in patients with HIV. |
| Q46442340 | Can Biomarkers Advance HIV Research and Care in the ART Era? |
| Q34342368 | Chronic HIV disease and activation of the coagulation system |
| Q33614424 | Coagulation and morbidity in treated HIV infection |
| Q40367422 | Coagulation imbalance and neurocognitive functioning in older HIV-positive adults on suppressive antiretroviral therapy |
| Q35992200 | D-Dimer Levels before HIV Seroconversion Remain Elevated Even after Viral Suppression and Are Associated with an Increased Risk of Non-AIDS Events |
| Q104100068 | Developing and validating a clinical warfarin dose-initiation model for Black-African patients in South Africa and Uganda |
| Q89704553 | Factor Xa Inhibition Reduces Coagulation Activity but Not Inflammation Among People With HIV: A Randomized Clinical Trial |
| Q35120065 | Factors associated with D-dimer levels in HIV-infected individuals |
| Q87632997 | HIV infection as a permanent, acquired risk factor for VTE |
| Q36360872 | Immune activation and HIV-specific T cell responses are modulated by a cyclooxygenase-2 inhibitor in untreated HIV-infected individuals: An exploratory clinical trial |
| Q38603237 | Immune activation in the course of HIV-1 infection: Causes, phenotypes and persistence under therapy |
| Q57822378 | In silico thrombin generation: Plasma composition imbalance and mortality in human immunodeficiency virus |
| Q64077947 | Inflammatory biomarkers and subclinical carotid atherosclerosis in HIV-infected and HIV-uninfected men in the Multicenter AIDS Cohort Study |
| Q38601647 | Inflammatory monocytes expressing tissue factor drive SIV and HIV coagulopathy. |
| Q35558823 | Lymphoid fibrosis occurs in long-term nonprogressors and persists with antiretroviral therapy but may be reversible with curative interventions |
| Q27024262 | Markers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patients |
| Q38161459 | Modeling thrombin generation: plasma composition based approach |
| Q37723466 | Multiple roles of the coagulation protease cascade during virus infection |
| Q37587740 | Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues |
| Q33452454 | Predictors of willingness to use a smartphone for research in underserved persons living with HIV. |
| Q38749963 | Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection |
| Q35021902 | Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation |
| Q33640033 | Similarity in viral and host promoters couples viral reactivation with host cell migration |
| Q47095325 | Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial |
| Q33577551 | Systemic effects of inflammation on health during chronic HIV infection |
| Q26772131 | The Importance of Thrombin in Cerebral Injury and Disease |
| Q28300749 | The end of AIDS: HIV infection as a chronic disease |
| Q41659122 | The evaluation of platelet indices and markers of inflammation, coagulation and disease progression in treatment-naïve, asymptomatic HIV-infected individuals. |
| Q40105787 | The role of the tissue factor and its inhibitor in the development of subclinical atherosclerosis in people living with HIV. |
| Q35785698 | Thromboelastography on plasma reveals delayed clot formation and accelerated clot lyses in HIV-1 infected persons compared with healthy controls |
| Q97640542 | Venous thromboembolism in people living with HIV infection (PWH) |
| Q91782016 | Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial |
Search more.